Remedy Robotics Raises $62M Series B for a Stroke Robot That Could Operate Remotely
In stroke care the enemy is the drive. A clot-removal procedure needs a specialist in a cath lab, and most hospitals do not have one on call. Remedy Robotics wants the specialist to be a robot, operated on site, from far away, or eventually on its own. On Monday it announced a $62M Series B led by DCVC. Release: https://www.prnewswire.com/news-releases/remedy-robotics-raises-62-million-series-b-to-bring-life-saving-cardiovascular-intervention-to-patients-everywhere-302939871.html
New investors are UC Investments, Skip Capital and Hostplus. Existing backers Build Collective (Tony Fadell's fund), Blackbird, Divergent Capital and KdT Ventures returned. Valuation was not disclosed. The company was co-founded by CEO Dr. David Bell and CTO Jake Sganga.
The product is the N1 System, an endovascular robot plus software. Machine learning reads the pre-operative scans, the procedure gets simulated in advance, and real-time 3D-to-2D image registration lets the robot track where its catheter is inside the vessel. Remedy says N1 can carry out an entire endovascular procedure robotically. It works with more than 100 hospitals and with stroke networks such as SVIN Mission Thrombectomy and the Australian Stroke Alliance.
The money funds a pivotal trial across the University of California network, the path toward FDA approval for neurovascular intervention, prototype deployments and work on full autonomy. The important caveat, stated in the release itself: N1 is not available for sale or clinical use anywhere yet. This is a bet on regulators, not a product in hospitals.
← Back to all articles
New investors are UC Investments, Skip Capital and Hostplus. Existing backers Build Collective (Tony Fadell's fund), Blackbird, Divergent Capital and KdT Ventures returned. Valuation was not disclosed. The company was co-founded by CEO Dr. David Bell and CTO Jake Sganga.
The product is the N1 System, an endovascular robot plus software. Machine learning reads the pre-operative scans, the procedure gets simulated in advance, and real-time 3D-to-2D image registration lets the robot track where its catheter is inside the vessel. Remedy says N1 can carry out an entire endovascular procedure robotically. It works with more than 100 hospitals and with stroke networks such as SVIN Mission Thrombectomy and the Australian Stroke Alliance.
The money funds a pivotal trial across the University of California network, the path toward FDA approval for neurovascular intervention, prototype deployments and work on full autonomy. The important caveat, stated in the release itself: N1 is not available for sale or clinical use anywhere yet. This is a bet on regulators, not a product in hospitals.
Comments